Asset Details
Do you wish to reserve the book?
Circulating biomarkers in patients with glioblastoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Circulating biomarkers in patients with glioblastoma
Do you wish to request the book?
Circulating biomarkers in patients with glioblastoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Circulating biomarkers in patients with glioblastoma
2020
Overview
Gliomas are the most common tumours of the central nervous system and the most aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival remains low. GBM diagnosis typically relies on imaging techniques and postoperative pathological diagnosis; however, both procedures have their inherent limitations. Imaging modalities cannot differentiate tumour progression from treatment-related changes that mimic progression, known as pseudoprogression, which might lead to misinterpretation of therapy response and delay clinical interventions. In addition to imaging limitations, tissue biopsies are invasive and most of the time cannot be performed over the course of treatment to evaluate ‘real-time’ tumour dynamics. In an attempt to address these limitations, liquid biopsies have been proposed in the field. Blood sampling is a minimally invasive procedure for a patient to endure and could provide tumoural information to guide therapy. Tumours shed tumoural content, such as circulating tumour cells, cell-free nucleic acids, proteins and extracellular vesicles, into the circulation, and these biomarkers are reported to cross the blood–brain barrier. The use of liquid biopsies is emerging in the field of GBM. In this review, we aim to summarise the current literature on circulating biomarkers, namely circulating tumour cells, circulating tumour DNA and extracellular vesicles as potential non-invasively sampled biomarkers to manage the treatment of patients with GBM.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Biomarkers, Tumor - metabolism
/ Biomedical and Life Sciences
/ Biopsy
/ Blood-Brain Barrier - metabolism
/ Brain Neoplasms - diagnostic imaging
/ Brain Neoplasms - metabolism
/ Cell-Free Nucleic Acids - metabolism
/ Circulating Tumor DNA - metabolism
/ Extracellular Vesicles - metabolism
/ Glioblastoma - diagnostic imaging
/ Glioma
/ Humans
/ Neoplasm Proteins - metabolism
/ Neoplastic Cells, Circulating - metabolism
/ Oncology
/ Patients
/ Review
/ Tumors
/ Vesicles
